このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Meridian Bioscience マネジメント

マネジメント基準チェック /34

Meridian Bioscience'sの CEO はJack Kennyで、 Oct2017年に任命され、の在任期間は 5.33年です。の年間総報酬は$ 4.60Mで、 15.4%給与と84.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.28%を直接所有しており、その価値は$ 4.17M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と6.8年です。

主要情報

Jack Kenny

最高経営責任者

US$4.6m

報酬総額

CEO給与比率	15.4%
CEO在任期間	5.3yrs
CEOの所有権	0.3%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27

CEO報酬分析

Meridian Bioscience の収益と比較して、Jack Kenny の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2022	US$5m	US$710k	US$42m
Jun 30 2022	n/a	n/a	US$43m
Mar 31 2022	n/a	n/a	US$62m
Dec 31 2021	n/a	n/a	US$60m
Sep 30 2021	US$3m	US$690k	US$71m
Jun 30 2021	n/a	n/a	US$71m
Mar 31 2021	n/a	n/a	US$87m
Dec 31 2020	n/a	n/a	US$70m
Sep 30 2020	US$3m	US$670k	US$46m
Jun 30 2020	n/a	n/a	US$44m
Mar 31 2020	n/a	n/a	US$21m
Dec 31 2019	n/a	n/a	US$19m
Sep 30 2019	US$1m	US$650k	US$24m
Jun 30 2019	n/a	n/a	US$26m
Mar 31 2019	n/a	n/a	US$27m
Dec 31 2018	n/a	n/a	US$26m
Sep 30 2018	US$2m	US$542k	US$24m

報酬と市場: Jackの総報酬 ($USD 4.60M ) は、 US市場 ($USD 5.67M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jackの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Jack Kenny (53 yo)

5.3yrs

在職期間

US$4,598,825

報酬

Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017. Mr. Kenny serves as President of Meridian Bioscience, Inc. and served as its...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Kenny	President	5.3yrs	US$4.60m	0.28% $ 4.2m
Andrew Kitzmiller	Executive VP & CFO	less than a year	US$1.03m	0.0092% $ 137.4k
Julie Smith	Senior VP	1.2yrs	US$786.42k	0.097% $ 1.5m
Lourdes Weltzien	Executive Vice President of Life Science Business Unit	9.4yrs	US$1.23m	0.13% $ 2.0m
Tony Serafini-Lamanna	Executive Vice President of Diagnostics	2.8yrs	US$1.20m	0.038% $ 567.0k
Jeff Pinkston	Director of Corporate Finance	no data	データなし	データなし
Charles Wood	Vice President of Corporate Strategy	3.1yrs	データなし	データなし
Emerson Moser	Senior VP & General Counsel	less than a year	データなし	データなし
Melissa McCarey	Vice President of Global Human Resources	4.8yrs	データなし	データなし
Susan Rolih	Consultant	4.3yrs	US$626.75k	データなし
Melissa Lueke	Consultant	4.1yrs	US$432.97k	データなし

3.6yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: VIVOの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
John Kenny	President	6.1yrs	US$4.60m	0.28% $ 4.2m
John Rice	Independent Director	5.5yrs	US$176.25k	0.056% $ 833.6k
John McIlwraith	Chairman	7.5yrs	US$212.75k	0.043% $ 638.2k
James Anderson	Independent Director	13.6yrs	US$197.00k	0.069% $ 1.0m
Felicia Williams	Independent Director	4.4yrs	US$192.50k	0.017% $ 247.7k
Anthony Bihl	Independent Director	2.6yrs	US$189.63k	0.028% $ 422.8k
Dwight Ellingwood	Independent Director	8.6yrs	US$177.50k	0.033% $ 487.1k
Catherine Sazdanoff	Independent Director	7.5yrs	US$191.13k	0.031% $ 457.5k

6.8yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: VIVOの取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

Meridian Bioscience マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Independent Director exercised options to buy US$285k worth of stock.

Insufficient new directors

President exercised options and sold US$1.1m worth of stock

Insufficient new directors

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Meridian Bioscience, Inc. Announces Board Changes

Recent updates

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$34.00

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience: High-Probability Merger Arbitrage

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Bioscience: Correctly Valued

President exercised options and sold US$1.1m worth of stock

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience: Deceptively Priced

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

Price target increased to US$30.00

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Key Executive exercised options to buy US$157k worth of stock.

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Price target decreased to US$27.00

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Price target decreased to US$30.50

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Consensus forecasts updated

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Investor sentiment deteriorated over the past week

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

President recently sold US$250k worth of stock

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix

Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides an Update on the Revogene SARS-CoV-2 EUA Submission

マネジメント基準チェック /34